Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP-CBD
- Development stage
- Unknown
- Lead developer
- Indaptus Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**AP-CBD** is an investigational oral formulation of cannabidiol (CBD) developed by Intec Pharma using proprietary Accordion Pill technology for targeted gastrointestinal delivery. It is being evaluated in combination with THC (as AP-CBD/THC) primarily for pain management, leveraging CBD's multimodal effects including negative allosteric modulation of CB1 receptors, anti-inflammatory activity via cyclooxygenase and lipoxygenase inhibition, and anticonvulsant properties, though specific indications focus on chronic pain conditions.[9]
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ADRA1A (α1A)CNR1 (Cannabinoid receptor 1)MOR (Mu opioid receptor)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPV2 (Transient receptor potential cation channel subfamily V member 2)
Beyond the preview
Go deeper on AP-CBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP-CBD.